GeneDx (WGS) to Release Quarterly Earnings on Tuesday

GeneDx (NASDAQ:WGS) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect the company to announce earnings of $0.33 per share and revenue of $104.3250 million for the quarter. GeneDx has set its FY 2025 guidance at EPS.Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.40. The firm had revenue of $102.69 million during the quarter, compared to analyst estimates of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Stock Performance

NASDAQ WGS opened at $128.87 on Friday. The firm has a market cap of $3.70 billion, a price-to-earnings ratio of 2,577.40 and a beta of 1.98. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average price of $123.22 and a 200-day moving average price of $97.73. GeneDx has a twelve month low of $55.17 and a twelve month high of $136.00.

Insider Buying and Selling

In related news, CEO Katherine Stueland sold 10,501 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the sale, the chief executive officer owned 14,578 shares in the company, valued at approximately $1,770,789.66. This represents a 41.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jason Ryan sold 38,072 shares of the stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director owned 103,284 shares in the company, valued at $13,148,053.20. The trade was a 26.93% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 556,371 shares of company stock worth $67,489,314. 29.60% of the stock is currently owned by corporate insiders.

Institutional Trading of GeneDx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Morse Asset Management Inc raised its holdings in GeneDx by 34.2% during the 2nd quarter. Morse Asset Management Inc now owns 27,385 shares of the company’s stock valued at $2,528,000 after buying an additional 6,974 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of GeneDx by 257.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,335 shares of the company’s stock worth $2,523,000 after buying an additional 19,694 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after buying an additional 11,375 shares during the period. California State Teachers Retirement System raised its holdings in shares of GeneDx by 38.6% in the second quarter. California State Teachers Retirement System now owns 20,992 shares of the company’s stock worth $1,938,000 after buying an additional 5,846 shares during the period. Finally, MML Investors Services LLC purchased a new stake in shares of GeneDx in the second quarter worth approximately $1,359,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on WGS shares. Canaccord Genuity Group set a $155.00 price objective on GeneDx and gave the stock a “buy” rating in a research note on Monday, October 20th. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research report on Friday. Guggenheim reiterated a “buy” rating and issued a $115.00 target price (up from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Piper Sandler boosted their target price on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. Finally, Wall Street Zen upgraded GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $112.80.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.